报价延迟最少15分钟:2026/01/07 16:05 EST
盘后时段
|
||||
|
21.98 
|
|
|
常规时段 (已结束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
21.94
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.55/-0.74
|
|
企业价值
15.12B
|
| 资产负债 |
|
每股账面净值
6.27
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
29.05M
|
|
每股收益
0.11
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others. |
